Thus, targeted therapies aimed at blocking the autocrine/paracrine FGF19/FGFR-4 loop might serve as effective treatments in a subset of HCC patients with FGF19/FGFR-4-driven tumors. Here, FGF19 is linked to hepatocellular carcinoma.